<DOC>
	<DOCNO>NCT02690337</DOCNO>
	<brief_summary>This open-label study evaluate safety , tolerability , pharmacokinetics DS-1123a Japanese subject advance solid tumor .</brief_summary>
	<brief_title>Study DS-1123a Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Advanced solid tumor refractory standard treatment , standard treatment available . Eastern Cooperative Oncology Group performance status ( PS ) 0 1 . Have follow concomitant disease history follow disease within 6 month enrollment : • Cardiac failure ( NYHA ≥ ClassIII ) , myocardial infarction , cerebral infarction , unstable angina , arrhythmia require treatment , coronaryartery/peripheral artery bypass surgery , cerebrovascular disease , pulmonary thromboembolism , deepvein thrombosis clinically severe thromboembolic event , clinically severe pulmonary disease ( eg , interstitial pneumonia , pulmonary fibrosis , radiation pneumonia , drug induce pneumonia ) , Severe uncontrolled concomitant disease . Clinically active brain metastasis define symptomatic requiring treatment .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Advanced solid malignant tumor</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
	<keyword>refractory</keyword>
	<keyword>standard treatment</keyword>
</DOC>